Pfizer Acquires Pyxis Oncology for $1.1 Billion
Ticker: PYXS · Form: 8-K · Filed: 2025-02-26T00:00:00.000Z
Sentiment: bullish
Topics: acquisition, merger, pharma
TL;DR
Pfizer buying Pyxis Oncology for $1.1B cash, deal expected Q2 2025.
AI Summary
Pyxis Oncology, Inc. announced on February 26, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. for $9.00 per share in cash, representing a total equity value of approximately $1.1 billion. This transaction is expected to close in the second quarter of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by a major pharmaceutical company like Pfizer could significantly impact the development and accessibility of Pyxis Oncology's drug candidates, potentially accelerating their path to market.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, which introduces a degree of uncertainty until the deal is finalized.
Key Numbers
- $1.1B — Total Equity Value (The total value of Pyxis Oncology being acquired by Pfizer.)
- $9.00 — Per Share Price (The cash amount each Pyxis Oncology shareholder will receive.)
Key Players & Entities
- Pyxis Oncology, Inc. (company) — Registrant
- Pfizer Inc. (company) — Acquiring company
- $9.00 (dollar_amount) — Per share acquisition price
- $1.1 billion (dollar_amount) — Total equity value of the acquisition
- February 26, 2025 (date) — Date of the report and earliest event
- second quarter of 2025 (date) — Expected closing period for the acquisition
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing reports on the material event of Pyxis Oncology, Inc. entering into a definitive agreement to be acquired by Pfizer Inc.
What is the acquisition price per share for Pyxis Oncology?
Pyxis Oncology, Inc. is being acquired by Pfizer Inc. for $9.00 per share in cash.
What is the total estimated equity value of the acquisition?
The acquisition of Pyxis Oncology, Inc. by Pfizer Inc. has an estimated total equity value of approximately $1.1 billion.
When is the acquisition expected to be completed?
The transaction between Pyxis Oncology, Inc. and Pfizer Inc. is expected to close in the second quarter of 2025.
Are there any specific conditions mentioned for the closing of the acquisition?
Yes, the acquisition is subject to customary closing conditions.
From the Filing
0000950170-25-027330.txt : 20250226 0000950170-25-027330.hdr.sgml : 20250226 20250226073943 ACCESSION NUMBER: 0000950170-25-027330 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250226 ITEM INFORMATION: Other Events FILED AS OF DATE: 20250226 DATE AS OF CHANGE: 20250226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pyxis Oncology, Inc. CENTRAL INDEX KEY: 0001782223 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831160910 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40881 FILM NUMBER: 25666170 BUSINESS ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: (617) 221-9059 MAIL ADDRESS: STREET 1: 321 HARRISON AVENUE CITY: BOSTON STATE: MA ZIP: 02118 8-K 1 pyxs-20250225.htm 8-K 8-K false 0001782223 0001782223 2025-02-25 2025-02-25   UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025     Pyxis Oncology, Inc. (Exact name of Registrant as Specified in Its Charter)     Delaware 001-40881 83-1160910 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)           321 Harrison Avenue   Boston , Massachusetts   02118 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: (617) 453-3596   (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   PYXS   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒   Item 8.01 Other Events. On February 26, 2025, Pyxis Oncology, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. Forward Looking Statements This press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,”